123I-MIBG and 111In-pentetreotide scintigraphy should not be used as first-line imaging studies for initial tumour screening in asymptomatic SDHA, SDHB, SDHC or SDHD-pi mutation carriers (Grade A). Here, SDHD is linked to neoplasm.